Jupiter Neurosciences Doses First Patient In Parkinson's Trial
Jupiter Neurosciences Inc. has dosed the first patient in its Phase 2A Reset Trial for Parkinson's Disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Jupiter Neurosciences Doses First Patient in Parkinson's Phase 2a Trial, Explores Strategic Options
Jupiter Neurosciences has dosed the first patient in its Phase 2a RESET trial evaluating JOTROL™ for Parkinson's disease. The company has also retained Tungsten Advisors to explore strategic options to maximize shareholder value.